Neglected Tropical Disease News and Research

RSS

Streamlining clinical trials review process to speed up delivery of drugs to those in need

In this Atlantic opinion piece, Amanda Glassman, director of Global Health Policy at the Center for Global Development (CGD), reports on how lengthy, inefficient review processes for drug and vaccine candidates waiting in the pipeline for late stages of clinical development is keeping promising new medicines, vaccines, and diagnostic techniques from reaching millions in need.

16 Nov 2011

Researchers to begin drug development projects for rare and neglected diseases

Researchers will begin drug development projects for rare and neglected diseases that include potential treatments for a musculoskeletal disorder, a cognitive dysfunction disorder, a virus that affects the central nervous system of newborns, a parasitic worm infection, a form of muscular dystrophy and a rare lung disease.

16 Nov 2011

IVI receives WHO prequalification for new oral cholera vaccine

Shanchol-, a new oral cholera vaccine developed through the International Vaccine Institute (IVI), an international organization established by the United Nations and based in Seoul, recently received prequalification from the World Health Organization.

13 Nov 2011

Pharmaceutical industry should invest more in NTDs

In this Forbes opinion piece, contributor Sarika Bansal examines "what needs to happen for the pharmaceutical industry, academic researchers, and other key players to begin investing more seriously in" neglected tropical diseases.

11 Nov 2011

OWH to participate in major kala-azar elimination project

OneWorld Health (OWH) announced that it will participate in a major consortium project aimed to boost strategies for control and eventual elimination of visceral leishmaniasis (VL or kala-azar) in India and Bangladesh, where the disease burden is among the world's highest.

10 Nov 2011

Four-year kala azar treatment study launched in India, Bangladesh

"A four-year test of drugs to treat a widespread parasitic disease called kala azar was announced on Monday by the governments of India and Bangladesh, Doctors Without Borders, the Drugs for Neglected Diseases Initiative [DNDi] and other groups," the New York Times reports.

9 Nov 2011

CGD releases report on improving clinical trials, regulatory pathways for fighting neglected diseases

The Center for Global Development (CGD) last week released a new report on global health, the Global Health Technology Coalition's "Breakthroughs" blog reports.

8 Nov 2011

Largest-ever implementation study on kala-azar in Asia

A comprehensive four-year project including over 10,000 patients in clinical and pharmacovigilance studies for diagnosis and treatment of visceral leishmaniasis (VL, also known as kala-azar) in India and Bangladesh was launched by an international consortium formed last month to support control and elimination strategies in both countries, where the concentration of disease burden is among the world's highest.

7 Nov 2011

Global Health Technologies Coalition blog reports on health research projects in Kenya

In a post in the Global Health Technologies Coalition's "Breakthroughs" blog, GHTC's Kim Lufkin reports on her travels to Kenya this month "to visit global health research projects and see the impact on people in the country," writing, "Although we visited a range of projects, I was left with the lasting impression that much of this research is so close to producing new health tools that can lead to amazing innovations in public health," including "the first ever malaria vaccine, gels women can use to protect themselves from HIV, and new drugs for neglected diseases that affect the poorest of the poor."

29 Oct 2011

Scientists identify nicotinamidase enzyme as new drug target for Leishmaniasis

IRD scientist and their research partners recently identified the key role of nicotinamidase, an enzyme in the parasite Leishmania, essential for its survival but which does not exist in humans. The pathogen is incapable of developing in mammals In the absence of this enzyme. Specific targeting of this enzyme could lead to more effective ways of controlling this neglected tropical disease.

29 Oct 2011

WHO, partners prepare to launch database for sharing intellectual property

"The World Intellectual Property Organization, in conjunction with the World Health Organization, private sector and foundation partners, is preparing to launch a new voluntary database for the sharing of intellectual property for research and development on medicines, vaccines and diagnostics for neglected diseases, according to sources in Geneva," Intellectual Property Watch reports.

21 Oct 2011

Experimental vaccine halves risk of malaria in African children, results of large clinical trial suggest

"An experimental vaccine from GlaxoSmithKline halved the risk of African children getting malaria in a major clinical trial, making it likely to become the world's first shot against the deadly disease," according to a study "presented at the Bill & Melinda Gates Foundation's Malaria Forum conference in Seattle and published simultaneously in the New England Journal of Medicine" on Tuesday, Reuters reports.

20 Oct 2011

Study finds experimental vaccine protects monkeys from blinding trachoma

"An attenuated, or weakened, strain of Chlamydia trachomatis bacteria can be used as a vaccine to prevent or reduce the severity of trachoma, the world's leading cause of infectious blindness, suggest findings from a National Institutes of Health (NIH) study in monkeys," an NIH press release reports.

12 Oct 2011

Potential vaccine against trachoma

An attenuated, or weakened, strain of Chlamydia trachomatis bacteria can be used as a vaccine to prevent or reduce the severity of trachoma, the world's leading cause of infectious blindness, suggest findings from a National Institutes of Health study in monkeys.

10 Oct 2011

High prevalence of NTDs in Central Asia after 1991 collapse of the Soviet Union

The open-access journal PLoS Neglected Tropical Diseases will publish an article emphasizing the rising burden of Neglected Tropical Diseases (NTDs) in Central Asia on Tuesday, Sept. 27th.

28 Sep 2011

UCI professor wins Presidential Early Career Award for Scientists & Engineers

Rommie Amaro, UC Irvine assistant professor of pharmaceutical sciences and computer science, has been selected by President Obama for the Presidential Early Career Award for Scientists & Engineers.

28 Sep 2011

Afraxis to participate in NIH's Therapeutics for Rare and Neglected Disease Program

Afraxis, a San Diego-based biotechnology company developing drugs to treat rare genetic diseases through the modulation of p21-activated kinase (PAK), announced today that it has been selected to participate in the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Disease (TRND) Program.

27 Sep 2011

Sodium Stibogluconate & Paromomycin combination treatment for Kala azar

East Africa is fighting the worst kala azar outbreak in a decade. Collaboration across the region through the Leishmaniasis East Africa Platform (LEAP) has resulted in the development of a new combination therapy (SSG&PM) which is cheaper and nearly halves the length of treatment from a 30 day course of injections to 17 days.

26 Sep 2011

More funding for leishmaniasis treatment could save more lives in East African outbreak

"East Africa's worst outbreak in a decade of visceral leishmaniasis, the deadliest parasitic disease after malaria, could ease if donors paid more attention to the illness," which infects approximately 500,000 people and kills up to 60,000 annually in 70 countries, the non-profit group "Leishmaniasis East Africa Platform, or LEAP, said in a statement from Nairobi" on Friday, Bloomberg reports.

23 Sep 2011

Supplement in USA Today highlights global NTD eradication efforts

This supplement (.pdf) by Mediaplanet, distributed in the September 15 issue of USA Today in select cities nationwide, examines the latest programs dedicated to eradicating neglected tropical diseases (NTDs) worldwide.

17 Sep 2011